Drug Type Small molecule drug |
Synonyms Prinaberel (USAN/INN), ERB-041, PF-00913086 + [1] |
Target |
Action agonists |
Mechanism ERβ agonists(Estrogen receptor beta agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H10FNO3 |
InChIKeyMQIMZDXIAHJKQP-UHFFFAOYSA-N |
CAS Registry524684-52-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06631 | Prinaberel | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dysmenorrhea | Phase 2 | United States | 01 May 2006 | |
Dysmenorrhea | Phase 2 | Australia | 01 May 2006 | |
Dysmenorrhea | Phase 2 | Belgium | 01 May 2006 | |
Dysmenorrhea | Phase 2 | Canada | 01 May 2006 | |
Dysmenorrhea | Phase 2 | Hong Kong | 01 May 2006 | |
Dysmenorrhea | Phase 2 | South Africa | 01 May 2006 | |
Dysmenorrhea | Phase 2 | United Kingdom | 01 May 2006 | |
Dyspareunia | Phase 2 | United States | 01 May 2006 | |
Dyspareunia | Phase 2 | Australia | 01 May 2006 | |
Dyspareunia | Phase 2 | Belgium | 01 May 2006 |
Phase 2 | 291 | ERB-041/ placebo | ftllcrvkix(jejqwpyisn) = No statistically significant difference for the ACR20 was found between the ERB-041 treatment and placebo groups (P = 0.518). djxzdkxnwu (ssxnbgndsd ) View more | Negative | 01 Nov 2010 |